Antimicrobial Combination Therapy for Treatment of Enterococcus Faecalis Bacteremia
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorIRCCS Azienda Ospedaliero-Universitaria di Bologna
About this trial
Prospective, multicenter, national, observational pharmacological study on the evaluation of efficacy of appropriate monotherapy vs combination treatment for non-complicated Enterococcus faecalis (EF) bloodstream infection (BSI) and identification of gut microbiota fingerprint of patients with EF-BSI correlated to antimicrobial treatment and clinical outcome
Eligibility criteria
Qualifiers
Adult (≥18 years)
Monomicrobial EF-BSI
Receipt of ≥ 5 days of at least one in vitro active drug (ampicillin, amoxicillin/clavulanate, ampicillin/sulbactam, piperacillin, vancomycin, teicoplanin, daptomycin and linezolid) with or without a synergistic drug (ceftriaxone, gentamycin, streptomycin), at common suggested dosages for EF-BSI in empirical or definitive therapy
Written informed consent
Disqualifiers
Short term (within 3 days from BSI) mortality
Other concomitant infection
Trial design
Treatments tested in this trial
- Not listed
Trial groups
510 Participants
are grouped into 1 trial groupLocations
4IRCCS Azienda Ospedaliero-Universitaria di Bologna40138, BolognaBologna, Italy
Ospedale Maggiore "Carlo Alberto Pizzardi" di Bologna40133, BolognaBologna, Italy
Azienda Ospedaliero Universitaria di Catanzaro "Mater Domini"88100, CatanzaroCatanzaro, Italy
Humanitas Research Hospital20089, MilanMilano, Italy
Sponsors and collaborators
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Lead sponsor
Source ClinicalTrials.gov